Related Experiment Videos
DNA and RNA-based vaccines: principles, progress and prospects.
W W Leitner1, H Ying, N P Restifo
1National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD 20892-1502, USA. wolfgang_leitner@nih.gov
Vaccine
|December 2, 1999
Summary
Self-replicating genetic vaccines, utilizing RNA replicase, show enhanced immunogenicity by mimicking viral infections. This approach, involving double-stranded RNA, effectively activates dendritic cells for improved therapeutic vaccination strategies.
Area of Science:
- Vaccinology
- Molecular Biology
- Immunology
Background:
- DNA vaccines offer broad applications for infectious and malignant diseases.
- Current genetic vaccines require enhancement for therapeutic efficacy in clinical trials.
Purpose of the Study:
- To review mechanisms of DNA vaccine activity and strategies for enhancement.
- To explore the potential of self-replicating genetic vaccines for improved immunogenicity.
Main Methods:
- Review of current literature on DNA vaccine mechanisms and enhancement strategies.
- Focus on immunostimulatory sequences (CpG), dendritic cells (DC), co-stimulatory molecules, and cytokine/chemokine adjuvants.
- Investigation of self-replicating RNA vectors encoding RNA replicase from alphaviruses.
Main Results:
- Self-replicating RNA vectors are significantly more immunogenic than conventional plasmids.
- Low doses (0.1 microg) of self-replicating vectors effectively immunize mice.
- Antigen production followed by apoptotic cell death, potentially due to double-stranded (ds) RNA intermediates, enhances immune activation.
Conclusions:
- Self-replicating genetic vaccines demonstrate dramatically increased immunogenicity.
- Pro-inflammatory dsRNA production in self-replicating vaccines mimics viral infection, leading to super-activated dendritic cells.
- This enhanced immunogenicity holds promise for therapeutic vaccination against infectious diseases and cancer.